Angela Epp

Medicine · Health Sciences

11h-index671citations29works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(11), CAR-T cell therapy research(8), Immunotherapy and Immune Responses(6), Glycosylation and Glycoproteins Research(5), HER2/EGFR in Cancer Research(4)

Publications29 total

Mindfulness as a Buffer Against Stress: A Moderation Analysis of University Student Psychological Well-Being
University of Calgary·2026Open Access
Screen Time and Online University Student Perceptions of Their Mental and Physical Well-Being
International journal on e-learning·2025
161P Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment
Annals of Oncology·2024· 3 citedOpen Access
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
Journal for ImmunoTherapy of Cancer·2023· 33 citedOpen Access
Abstract 1542: Generation of an antibody-drug conjugate-optimized TLR 7/8 agonist payload
Cancer Research·2023· 1 cited
1190 SGN-B7H4V induces immunomodulatory changes to the tumor microenvironment and pairs well with an anti-PD1 agent in a preclinical model
Regular and Young Investigator Award Abstracts·2022Open Access
Abstract 1766: SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models
Cancer Research·2022· 2 cited
Abstract 1281: SGN-B7H4V shows immunomodulatory activity through induction of immunogenic cell death
Cancer Research·2022
854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models
Regular and Young Investigator Award Abstracts·2021· 5 citedOpen Access
Abstract 50: Targeting Sialyl-Thomsen nouveau (STn) antigen with the SGN-STNV antibody-drug conjugate is effective in preclinical studies
Cancer Research·2021· 11 cited
Abstract 4994: SEA-CD40: from bench to bedside
Cancer Research·2016· 1 cited
Abstract 2469: Brentuximab vedotin-mediated immunogenic cell death
Cancer Research·2015· 46 cited
Abstract 2472: SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities
Cancer Research·2015· 6 cited
A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors.
Journal of Clinical Oncology·2015· 11 cited
Phosphorylation Of The Cytoplasmic Tyrosine Residues Of c-Mpl Is Not Required To Preserve Intact Receptor Dependent Hematopoietic Stem Cell Survival Signaling
Blood·2013
Proteomic analysis of the androgen receptor via MS‐compatible purification of biotinylated protein on streptavidin resin
PROTEOMICS·2011· 6 citedOpen Access
Suppression of the Immune Response to FVIII in Hemophilia A Mice by Transgene Modified Tolerogenic Dendritic Cells
Molecular Therapy·2011· 19 citedOpen Access
Suppression of FVIII Inhibitor Formation in Hemophilic Mice by Delivery of Transgene Modified Apoptotic Fibroblasts
Molecular Therapy·2009· 17 citedOpen Access
Suppression of the Immune Response to Human FVIII with FVIII Transgene Modified Tolerogenic Dendritic Cells in Hemophilia A Mice (89.42)
The Journal of Immunology·2009
Suppression of the Immune Responses to Factor VIII in the Hemophilia A Mice by Delivery of Transgene Modified Apoptotic Syngeneic Fibroblasts (89.36)
The Journal of Immunology·2009
page 1 of 2Next →

Frequent Co-authors

Shyra J. Gardai(11), Neil C. Josephson(10), Carol J. Raport(5), Patrick W. Gray(5), Ruijun Su(5), Christi L. Wood(4), David Chantry(4), Che‐Leung Law(4), Michelle Ulrich(4), Kelly Hensley(4), Sean Allred(4), Julie Hahn(4), Piper M. Treuting(4), John J. Gosink(4), Alyson Smith(4), Jason Schrum(4), Natalya Nazarenko(4), Xiaoping Wu(4), Vicki L. Schweickart(3), Elizabeth Gray(3)